{
    "clinical_study": {
        "@rank": "50401", 
        "arm_group": [
            {
                "arm_group_label": "Reference Drug - Abraxane", 
                "arm_group_type": "Active Comparator", 
                "description": "260 mg/m2 administered intravenously over 30 minutes on Day 1"
            }, 
            {
                "arm_group_label": "Test Drug - IG-001", 
                "arm_group_type": "Experimental", 
                "description": "260 mg/m2 administered intravenously over 30 minutes on Day 1"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to demonstrate bioequivalence of IG-001 versus Abraxane in\n      female patients with metastatic or locally recurrent breast cancer. In addition, the study\n      will compare the safety and tolerance of IG-001 and Abraxane during the bioequivalence\n      2-period crossover portion of the study. The study will also evaluate the long-term safety\n      of IG-001 over repeated cycles, up to 4 additional cycles of administration."
        }, 
        "brief_title": "Bioequivalence Study of IG-001 Versus Abraxane in Metastatic or Locally Recurrent Breast Cancer", 
        "completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Metastatic Breast Cancer", 
            "Locally Recurrent Breast Cancer"
        ], 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "This study is designed to compare the pharmacokinetics (PK) of IG-001 and Abraxane in\n      patients with metastatic or locally recurrent breast cancer. Patients meeting the\n      eligibility criteria will be randomized to determine which drug is administered first.\n\n        -  Patients randomized to Group 1 will receive a single dose of IG-001 (Period 1) followed\n           3 weeks later by a single dose of Abraxane (Period 2).\n\n        -  Patients randomized to Group 2 will receive a single dose of Abraxane (Period 1)\n           followed 3 weeks later by a single dose of IG-001 (Period 2).\n\n      Blood samples for PK analysis will be taken at specified times before, during, and after the\n      infusion of each drug in Periods 1 and 2. Following successful completion of Period 1 and\n      Period 2, patients may be eligible for up to 4 additional cycles of treatment with IG-001 in\n      the extension study.\n\n      Safety will be monitored throughout the study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Breast cancer patient who\n\n               1. Has histologically confirmed diagnosis of breast cancer.\n\n               2. Has stage IV or locally recurrent breast cancer per the American Joint Committee\n                  on Cancer Staging Manual (7th edition).\n\n               3. Has failed any single agent or combination chemotherapy for metastatic or\n                  locally recurrent disease.  Prior therapy should have included an anthracycline\n                  unless clinically contraindicated.\n\n               4. Has agreed to participate in the study and signed the informed consent form\n                  prior to participation in any study activities.\n\n          2. Sex and Age: Female > or = 30 years of age.\n\n          3. Body surface area (BSA) that is within 1.5 to 2.0 m2, calculated using the Mosteller\n             Formula.\n\n          4. Eastern Cooperative Oncology Group (ECOG) performance status < or = 1.\n\n          5. Sitting blood pressure (BP): systolic BP between 90-160 mmHg, inclusive, and\n             diastolic BP between 50-100 mmHg, inclusive, and radial pulse rate: 50-100 beats per\n             minute, inclusive.\n\n          6. Hematology/chemistry: adequate hematological, renal, and hepatic function within 7\n             days prior to randomization.\n\n          7. All other clinical laboratory values deemed normal or not clinically significant by\n             the Principal Investigator/Sub-Investigator.\n\n          8. Patients must be non-pregnant.\n\n          9. Patients must be non-lactating.\n\n         10. If sexually active, women of childbearing potential must agree to use contraception\n             considered adequate and appropriate by the Investigator (hormonal or barrier method,\n             abstinence) throughout the study and for 30 days after the last dose of study drug.\n\n         11. Able and willing to adhere to all protocol requirements and study procedures\n             throughout the study.\n\n         12. Ability to comprehend and be informed of the nature of the study, as assessed by\n             study clinic staff.\n\n        Exclusion Criteria:\n\n          1. Patients with a history of other malignancies, except for adequately treated\n             non-melanoma skin cancer, curatively treated in-situ carcinoma of the cervix or\n             breast, or other solid tumors curatively treated with no evidence of disease for > or\n             = 5 years.\n\n          2. Patients who have previously received Abraxane or IG-001.\n\n          3. Patients who received a taxane within the last 6 months prior to randomization.\n\n          4. Patients who have not completely recovered from any toxicities from previous\n             chemotherapy, hormone therapy, immunotherapy, or radiotherapy > or = Grade 1 per\n             National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events\n             (CTCAE) version 4.0, with the exception of alopecia.\n\n          5. Prior chemotherapy must be completed at least 30 days pror to randomization(42 days\n             for mitomycin C or nitrosoureas). Prior immunotherapy, prior anti-tumor hormonal\n             therapy, and prior radiotherapy must be completed at least 14 days prior to\n             randomization. Radiotherapy is not allowed during the study. Administration of other\n             chemotherapy, immunotherapy, or anti-tumor hormonal therapy during the study is not\n             allowed.\n\n          6. Patient had major surgery within 30 days prior to randomization, or patient has not\n             recovered from prior major surgery.\n\n          7. Sensory / Peripheral neuropathy of > Grade 1 per NCI CTCAE version 4.0 at Screening.\n\n          8. Patients with known brain metastases, with the exception of patients who have\n             completed surgery and/or radiotherapy at least 3 months prior to randomization, have\n             completed any steroids at least 3 months prior to randomization, and are currently\n             asymptomatic.\n\n          9. Known history or presence of any clinically significant disease or condition other\n             than cancer unless determined as not clinically significant by the Principal\n             Investigator/Sub-Investigator.\n\n         10. History of difficulty with donating blood or difficulty in accessibility of central\n             line.\n\n         11. Known history or presence of:\n\n               1. HIV, Hepatitis B, or Hepatitis C\n\n               2. Alcohol abuse or dependence within one year prior to randomization\n\n               3. Drug abuse or dependence within one year prior to randomization (marijuana,\n                  amphetamines, barbiturates, cocaine, opiates and benzodiazepines)\n\n               4. Hypersensitivity or idiosyncratic reaction to paclitaxel, its excipients, and/or\n                  related substances, including, albumin and PEG\n\n               5. Severe allergic reactions (e.g., anaphylactic reactions, angioedema)\n\n         12. Patients may not participate in any other clinical protocol or investigational trial\n             that involves administration of experimental therapy and/or the use of\n             investigational devices with therapeutic intent within 30 days prior to randomization\n             and while enrolled in this study.\n\n         13. Use of any strong inhibitors of cytochrome P450 (CYP) enzymes (e.g., fluoxetine,\n             quinidine, erythromycin, ciprofloxacin, fluconazole, ketoconazole, diltiazem and HIV\n             antivirals) and strong inducers of CYP enzymes (e.g., barbiturates (phenobarbital),\n             carbamazepine, phenytoin and rifampin), in the previous 14days before randomization\n             until the last blood draw in the final study period.\n\n         14. Acute active infection requiring antibiotics, antiviral agents, or antifungal agents\n             within 14 days prior to randomization.\n\n         15. Alcohol of any kind, grapefruit, and grapefruit juice within 48 hours prior to the\n             1st dose of study drug in each period until after the last blood draw in each period\n             (i.e., Day 4 of Cycle 1 and 2).\n\n         16. Patients with any significant history of non-compliance to medical regimens or with\n             inability to grant a reliable informed consent."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "30 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 14, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02064829", 
            "org_study_id": "STI-102"
        }, 
        "intervention": [
            {
                "arm_group_label": "Reference Drug - Abraxane", 
                "description": "260 mg/m2 administered intravenously over 30 minutes on Day 1 every 3 weeks", 
                "intervention_name": "Abraxane", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Paclitaxel albumin-bound particles for injectable suspension", 
                    "nab-paclitaxel"
                ]
            }, 
            {
                "arm_group_label": "Test Drug - IG-001", 
                "description": "260 mg/m2 administered intravenously over 30 minutes on Day 1 every 3 weeks", 
                "intervention_name": "IG-001", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Paclitaxel polymeric micelles for injectable suspension", 
                    "Genexol-PM"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Paclitaxel"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Metastatic breast cancer", 
            "Locally recurrent breast cancer", 
            "Bioequivalence", 
            "IG-001", 
            "Abraxane", 
            "Paclitaxel", 
            "Pharmacokinetics"
        ], 
        "lastchanged_date": "April 15, 2014", 
        "location": [
            {
                "contact": {
                    "email": "gbagwell@chemodok.com", 
                    "last_name": "Gena Bagwell", 
                    "phone": "423-622-2337"
                }, 
                "facility": {
                    "address": {
                        "city": "Chattanooga", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37421"
                    }, 
                    "name": "Associates in Oncology and Hematology"
                }, 
                "investigator": {
                    "last_name": "Jitendra Gandhi, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "cinman@westclinic.com", 
                    "last_name": "Cindy Inman, RN, OCN, CCRP", 
                    "phone": "901-683-0055", 
                    "phone_ext": "1236"
                }, 
                "facility": {
                    "address": {
                        "city": "Memphis", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "38120"
                    }, 
                    "name": "The West Clinic"
                }, 
                "investigator": {
                    "last_name": "Lee S Schwartzberg, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "samantha.yip.l.j@nccs.com.sg", 
                    "last_name": "Samantha Yip", 
                    "phone": "(65) 64368254"
                }, 
                "facility": {
                    "address": {
                        "city": "Singapore", 
                        "country": "Singapore", 
                        "zip": "169610"
                    }, 
                    "name": "National Cancer Centre Singapore"
                }, 
                "investigator": {
                    "last_name": "Mabel Wong, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Singapore"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "An Open-label, Randomized, Multi-center, Single-Dose, 2-Sequence, 2-Period, Crossover, Comparative Bioequivalence Study of IG-001 260 mg/m2 Versus Abraxane\u00ae 260 mg/m2 Administered Intravenously in Patients With Metastatic or Locally Recurrent Breast Cancer", 
        "overall_contact": {
            "email": "dbrown@acornresearch.net", 
            "last_name": "Deborah Brown", 
            "phone": "479-359-0318"
        }, 
        "overall_contact_backup": {
            "email": "erhea@acorncro.com", 
            "last_name": "Erica Rhea, CCRP", 
            "phone": "901-259-3231"
        }, 
        "overall_official": {
            "affiliation": "IgDraSol, Inc.", 
            "last_name": "Vuong Trieu, PhD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board", 
                "Singapore: Health Sciences Authority", 
                "Singapore: Institutional Review Board"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Maximum observed concentration of paclitaxel (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "Periods 1 and 2 - Predose; During infusion: 15 min and 30 min; Post-infusion: 15 min, 30 min, 1 hr, 1.5 hr, 2 hr, 4 hr, 6 hr, 8 hr, 12 hr, 24 hr, 48 hr, 72 hr"
            }, 
            {
                "measure": "Area under the concentration-time curve from time zero to infinite time of paclitaxel (AUC 0-inf)", 
                "safety_issue": "No", 
                "time_frame": "Periods 1 and 2 - Predose; During infusion: 15 min and 30 min; Post-infusion: 15 min, 30 min, 1 hr, 1.5 hr, 2 hr, 4 hr, 6 hr, 8 hr, 12 hr, 24 hr, 48 hr, 72 hr"
            }, 
            {
                "measure": "Area under the concentration-time curve from time zero to time t of paclitaxel (AUC 0-t)", 
                "safety_issue": "No", 
                "time_frame": "Periods 1 and 2 - Predose; During infusion: 15 min and 30 min; Post-infusion: 15 min, 30 min, 1 hr, 1.5 hr, 2 hr, 4 hr, 6 hr, 8 hr, 12 hr, 24 hr, 48 hr, 72 hr"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02064829"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Number of participants affected by treatment-emergent adverse events coded using the Medical Dictionary for Regulatory Activities (MedDRA)", 
            "safety_issue": "Yes", 
            "time_frame": "Up to 30 days after the last dose of study drug"
        }, 
        "source": "IgDraSol, Inc.", 
        "sponsors": {
            "collaborator": {
                "agency": "ACORN Research, LLC", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "IgDraSol, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}